Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making…

2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after…

Though far from the largest pharma market in Europe, Sweden nevertheless holds strategic importance for global pharma; from the country’s attitude…

Boehringer Ingelheim veteran executive Felix Gutsche shares the first impressions of the China market since he joined in January 2019; the strategic…

Thailand is becoming an increasingly attractive location for pharma companies to conduct clinical trials, with multinationals such as Novo Nordisk and…

Diabetes affects more than eight percent of the Thai population, a number that is on the rise, and nearly half of these cases remain undiagnosed. In…

Dr Armin Wiesler, general manager and head of Human Pharma at Boehringer Ingelheim (Thai) Ltd., explores how the affiliate has managed to achieve…

Andrea Sambatti is the general manager of Boehringer Ingelheim (BI) Sweden and is a member of the board of directors for LIF. Sambatti discusses how…

Against an alluring backdrop, big-name pharma brands are now starting to spend heavily on in-country manufacturing, development and shared service…

With Spain now on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are…

Timmo Andersen, general manager of Boehringer Ingelheim in Spain, explains how the affiliate has managed to achieve market-leading growth rates, the…

Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now,…